FGFR2 and infantile convulsions and choreoathetosis: Our experience corroborates these findings and supports the use of futibatinib as a treatment strategy for patients with FGFR2-rearranged iCCA who have progressed on cytotoxic chemotherapy and an ATP-competitive FGFR inhibitor.